Ghrelin Levels and Disease Localization in Inflammatory Bowel Disease: A Correlation Study

Year 2025, Volume: 15 Issue: 4, 320 - 327

Selcan Cesur , Ezgi Degerli , Yonca Yılmaz Ürün , Zeynep Karaali

Abstract

Aim: This study aimed to assess the relationship between ghrelin levels and factors such as disease localization, age, sex, disease duration, age at diagnosis, and biochemical parameters in inflammatory bowel disease (IBD).
Materials and Methods: The study included 87 patients (43 males, 44 females) with ulcerative colitis (UC) and Crohn’s disease (CD) aged 18–75 years, who applied to gastroenterology outpatient clinic. Exclusion criteria were chronic diseases other than UC and CD. Correlations between plasma ghrelin levels and disease characteristics were analyzed statistically.
Results: The mean patient age was 41.05 years (±11.6), and the mean age at diagnosis was 34.9 years (±11.3). Of the patients, 24 (27.6%) had CD, and 63 (72.4%) had UC. The most common site of involvement was the left colon (35%), while the highest ghrelin level was found in pancolitis cases (5.9176 ng/ml). However, no significant correlation was observed between ghrelin levels and sex, age, age at diagnosis, disease duration, type of IBD, localization of disease or biochemical parameters (C-reactive protein, sedimentation rate, hemoglobin, hematocrit, leukocyte levels).
Conclusion: Ghrelin levels were not indicative of disease localization in IBD patients in remission. However, based on previous research, ghrelin may hold potential as a marker for IBD diagnosis and activation rather than localization.

Keywords

Inflammatory bowel diseases , Ulcerative colitis , Crohn , Ghrelin

References

• Torres M, Rios A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol. 2008;14(13):1972. PMID:18395894; doi:10.3748/wjg.14.1972
• Travis SP, Stange EF, Lémann M, et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis. 2008 Mar;2(1):24-62. PMID:21172195; doi:10.1016/j.crohns.2007.11.002
• Tkach SM, Dorofeev AE, Kharchenko NV, Kwit CB. Biological functions and clinical significance of calprotectin. Review. Modern Gastroenterology. 2022 Sep 29;(3—4):34–41. doi:10.30978/MG-2022-3-34
• Buisson A, Gonzalez F, Poullenot F, et al. Comparative acceptability and perceived clinical utility of monitoring tools: A nationwide survey of patients with ınflammatory bowel disease. Inflamm Bowel Dis. 2017 Aug;23(8):1425-33. PMID:28570431; doi:10.1097/MIB.0000000000001140
• Cheung CK, Wu JC. Role of ghrelin in the pathophysiology of gastrointestinal disease. Gut Liver. 2013 Sep;7(5):505-12. PMID:24073306; doi:10.5009/gnl.2013.7.5.505
• Wu W, Zhu L, Dou Z, et al. Ghrelin in focus: Dissecting its critical roles in gastrointestinal pathologies and therapies. Curr Issues Mol Biol. 2024 Jan 22;46(1):948-64. PMID:38275675; doi:10.3390/cimb46010061
• Karmiris K, Koutroubakis IE, Kouroumalis EA. Leptin, adiponectin, resistin, and ghrelin--implications for inflammatory bowel disease. Mol Nutr Food Res. 2008 Aug;52(8):855-66. PMID:18383234; doi:10.1002/mnfr.200700050
• Pritchett NR, Maziarz M, Shu XO, et al. Serum ghrelin and esophageal and gastric cancer in two cohorts in China. Int J Cancer. 2020 May 15;146(10):2728-35. PMID:31351006; doi:10.1002/ijc.32597
• Sadjadi A, Yazdanbod A, Lee YY, et al. Serum ghrelin; a new surrogate marker of gastric mucosal alterations in upper gastrointestinal carcinogenesis. PLoS One. 2013;8(9):e74440. PMID:24098650; doi:10.1371/journal.pone.0074440
• Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis. 2006 Feb;12(2):100-5. PMID:16432373; doi:10.1097/01.MIB.0000200345.38837.46
• Kim SH, Jang SH, Kim JW, et al. Serum adipocytokine levels as surrogate markers for disease activity of Crohn's disease. Am J Med Sci. 2017 May;353(5):439-44. PMID:28502329; doi:10.1016/j.amjms.2017.02.006
• Eissa N, Ghia JE. Immunomodulatory effect of ghrelin in the intestinal mucosa. Neurogastroenterol Motil. 2015 Nov;27(11):1519-27. PMID:26503163; doi:10.1111/nmo.12703
• Peracchi M, Conte D, Terrani C, et al. Circulating ghrelin levels in celiac patients. Am J Gastroenterol. 2003 Nov;98(11):2474-8. PMID:14638351; doi:10.1111/j.1572-0241.2003.07709.x
• Ates Y, Degertekin B, Erdil A, Yaman H, Dagalp K. Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig Dis Sci. 2008 Aug;53(8):2215-21. PMID:18080768; doi:10.1007/s10620-007-0113-x
• Alexandridis E, Zisimopoulos A, Liratzopoulos N, Katsos I, Manolas K, Kouklakis G. Obestatin/ghrelin ratio: A new activity index in inflammatory bowel diseases. Inflamm Bowel Dis. 2009 Oct;15(10):1557-61. PMID:19408254; doi:10.1002/ibd.20940
• El-Salhy M. Ghrelin in gastrointestinal diseases and disorders: A possible role in the pathophysiology and clinical implications (review). Int J Mol Med. 2009 Dec;24(6):727-32. PMID:19885611; doi:10.3892/ijmm_00000285
• Khalaji A, Babajani N, Amirsardari Z, et al. Unveiling the ghrelin and obestatin roles in inflammatory bowel diseases: A systematic review and meta-analysis assessing their pathogenic implications and biomarker utility. Inflamm Bowel Dis. 2024 Apr 3;30(4):629-40. PMID:37669127; doi:10.1093/ibd/izad202
• Sahin M, Erdogan KE, Tekingündüz E. Correlation between the tissue ghrelin presence, disease activity and laboratory parameters in ulcerative colitis patients; immunohistochemical study. PLoS One. 2022;17(11):e0276065. PMID:36350879; doi:10.1371/journal.pone.0276065
• Nishi Y, Isomoto H, Ueno H, et al. Plasma leptin and ghrelin concentrations in patients with Crohn's disease. World J Gastroenterol. 2005 Dec 14;11(46):7314-7. PMID:16437634; doi:10.3748/wjg.v11.i46.7314